Telithromycin use and spontaneous reports of hepatotoxicity

Drug Safety

Volumn 30, Issue 8, 2007, Pages 697-703

  Dore, David D ^a   DiBello, Julia R ^a   Lapane, Kate L ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; TELITHROMYCIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; HUMAN; HYPOTHESIS; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; KETOLIDES; LIVER DISEASES; MALE; MIDDLE AGED; ODDS RATIO; UNITED STATES;

EID: 34548060926     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730080-00006     Document Type: Article

References (28)

1. Ketek (telithromycin) [product information]. Kansas City (MO): Aventis Pharmaceuticals, Inc., 2006 Jun
2. File TM. Telithromycin new product overview. J Allergy Clin Immunol 2005 Feb; 115 (2): 361-70
3. US Food and Drug Administration. FDA completes safety assessment of Ketek new safety information to be added to product labeling, 2006 [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01401.html [Accessed 2006 Jul 10]
4. Clay KD, Hanson JS, Pope SD, et al. Brief Communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006 Mar; 144 (6): 415-20
5. Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994; 33 (3): 387-401
6. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004 Aug; 13 (8): 519-23
7. Tellier G, Brunton SA, Nusrat R. Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent. South Med J 2005 Sep; 98 (9): 863-7
8. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 2003; 17: 369-77
9. Ferguson BL, Guzzetta RV, Spector S, et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 131 (3): 207-14
10. Fogarty C, de Wet R, Mandell L, et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005 Oct; 128 (4): 1980-8
11. Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002; 30 (6): 378-86
12. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006 Apr; 354 (15): 1589-600
13. Luterman M, Tellier G, Lasko B, et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 2003 Aug; 82 (8): 576-590
14. Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004; 26 (1): 48-62
15. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004 Aug; 54 (2): 515-23
16. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999 Feb; 20 (2): 109-17
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959 Apr; 22 (4): 719-48
18. Pringle E [IMS Health]. Scoop Independent News. Lawmakers demand answers about Ketek from FDA, 2006 [online]. Available from URL: http://www.scoop.co.nz/ stories/HL0606/S00279.htm [Accessed 2006 Jul 10]
19. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002 Dec; 137 (12): 947-54
20. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005 Dec; 3 (12): 1260-8
21. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004 Jun; 74 (3): 223-34
22. Moore AA, Gould R, Reuben DB, et al. Longitudinal patterns and predictors of alcohol consumption in the United States. Am J Public Health 2005 Mar; 95 (3): 458-65
23. Cox ER, Frisse M, Behm A, et al. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004 Jun; 164 (11): 1243-6
24. Rehm J, Room R, Graham K, et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 2003 Sep; 98 (9): 1209-28
25. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001 Aug; 286 (7): 831-3
26. Smalley WD, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000 Dec; 284 (23): 3036-9
27. Mazor KM, Andrade SE, Auger J, et al. Communicating safety information to physicians: an examination of dear doctor letters. Pharmacoepidemiol Drug Saf 2005 Dec; 14 (12): 869-75
28. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20 Suppl. C: 40-4